Cure My Disease

Don't miss your cure!

 Log in / Sign up

Surviving rare ovarian cancer: what comes next? new study investigates Long-Term fatigue and health

NCT ID NCT03418844

Ongoing Knowledge-focused Sponsor: Centre Francois Baclesse Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looks at women who have recovered from rare ovarian cancers (germ cell or sex cord-stromal tumors) to understand how the disease and chemotherapy affect their lives years later. Researchers will use questionnaires to measure chronic fatigue, quality of life, and other issues, and will also perform heart, lung, and hearing tests. The goal is to learn about the long-term side effects of treatment so doctors can better support survivors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this study could reveal how rare ovarian cancer and its treatments affect women's long-term health and daily life, guiding better follow-up care.
What could go wrong
This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not apply to all survivors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GERM CELL TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

germ cell tumor malignant germ cell tumor of ovary malignant non-epithelial tumor of ovary Neoplasms, Germ Cell and Embryonal ovarian sex cord-stromal tumor Sex Cord-Gonadal Stromal Tumors sex cord-stromal tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GERM CELL TUMOR MALIGNANT NON-EPITHELIAL OVARIAN TUMORS SEX CORD-STROMAL TUMOR

Contacts and locations

Locations

  • CH Fleyriat

    Bourg-en-Bresse, France

  • CHRU Stasbourg Hôpital Civil

    Strasbourg, France

  • CHU Besançon Jean MINJOZ

    Besançon, France

  • CHU Poitiers

    Poitiers, France

  • Centre Catherine de Sienne

    Nantes, France

  • Centre François Baclesse

    Caen, France

  • Centre Jean Perrin

    Clermont-Ferrand, France

  • Centre Léon Berard

    Lyon, France

  • Centre Paul Papin

    Angers, France

  • GH Cochin Broca Hôtel-Dieu

    Paris, France

  • HEGP

    Paris, Paris, France

  • Hôpital Diaconesses-Croix St Simon

    Paris, France

  • Institut Bergonié

    Bordeaux, France

  • Institut Curie,

    Paris, France

  • Institut Gustave Roussy

    Paris, France

  • Institut Jean Godinot

    Reims, France

  • Institut Paoli Calmettes

    Marseille, France

  • Institut Rennais de Cancérologie

    Rennes, France

  • Institut de Cancérologie de l'Ouest

    Nantes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.